Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). XOMA Royalty reorganized under a new holding company, preserving existing shareholder rights and equity awards.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- XOMA Royalty reorganized under a new holding company, preserving existing shareholder rights and equity awards
- XOMA Royalty LLC transferred designated business assets and liabilities to HoldCo before the merger
- CVR Trust received 75% of XOMA Royalty LLC’s units to fund contingent payments
- Stockholders received CVRs tied to future payments from the CVR Trust’s XOMA Royalty LLC interest
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merger with XOMA Royalty HoldCo completed July 14, 2026, converting XOMA shares into cash consideration and CVRs
- Common shareholders received $39.00 per share in cash, subject to withholding taxes
- CVRs provide contingent payments tied to the CVR Trust’s interest in XOMA Royalty LLC
- 8.625% Series A and 8.375% Series B preferred stock redeemed with accrued unpaid dividends
- Treatment of outstanding equity awards and warrants governed by the merger agreement
Item 7.01 · Regulation FD Disclosure
- Press release announces completion of the merger on July 14, 2026
- Merger completion marks a material corporate transaction for Ligand and its security holders
- Full transaction details provided in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Acquisition completed for $739 million, adding seven commercial products and over 100 development-stage assets
- Portfolio more than doubled to over 200 royalty assets, materially broadening Ligand’s revenue base
- Expected adjusted EPS accretion of approximately $0.50 in 2026 and $1.50 in 2027
- XOMA Royalty shareholders received $39.00 cash per share plus CVRs tied to 75% of certain litigation net proceeds
- XOMA Royalty shares ceased trading on Nasdaq; Ligand plans an updated five-year outlook on December 8, 2026
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.